Gastrointestinal Drugs Market size is expected to reach US$ 366.85 Bn. by year 2029 at a CAGR of 4.3% during the forecast period. Gastrointestinal drugs including promotility drugs, antimotility drugs, and drugs for acid-related disorders. The commonly used gastrointestinal drugs as a group are considered safe and are generally used. A range of neurologic complications is performed successive use of various gastrointestinal drugs.To know about the Research Methodology :- Request Free Sample Report Increasing prevalence of gastrointestinal disease universal and rising awareness and government initiatives are expected driving factors in the global gastrointestinal drugs market. Moreover, emerging generic drugs owing to its cost-effectiveness and the rising popularity of diseases such as irritable bowel syndrome are expected to be major factors attributed to the growth of the global market. However, the side effects associated with the drugs is restraint in the market. Rising investments in research and development activities for the innovation of novel drugs and the technological developments in the treatment process are major opportunities in the market. Based on the drug category, the anti-inflammatory drug segment is dominated by xx% market share in the forecast period. The anti-inflammatory drug segment is used to treat situations like arthritis, chronic obstructive pulmonary disease, and other diseases. Anti-inflammatory drugs are a growing incidence of these viruses is the main cause of improving the segment upwards. Gastroesophageal reflux disorder segment is expected to dominate the xx% market share during the forecast period. Owing to the increase in awareness between physicians and patients about the side effects of the proton pump inhibitors class of drugs. Gastroesophageal reflux disease is a chronic gastric disorder that happens because of problems arising in the esophagus. Gastroesophageal reflux disease is a chronic and highly prevalent medical problem during the forecast period. Regionally, Asia Pacific is expected to account for the largest share of the gastrointestinal drug market during the forecast period. The development of the healthcare and medical infrastructure increase in public and private investments for technological advancements and life sciences research. The treatments and medicinal processes of gastrointestinal syndromes or diseases in future economies, such as China and India, are estimated to fuel the global gastrointestinal drug market during the forecast period. The objective of the report is to present comprehensive analysis of global gastrointestinal drugs market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding global gastrointestinal drugs market dynamics, structure by analyzing the market segments, and project the global gastrointestinal drugs market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the global gastrointestinal drugs market make the report investor’s guide.
Scope of the Global Gastrointestinal Drugs Market: Inquire before buying
Global Gastrointestinal Drugs Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US $ 261.95 Bn. Forecast Period 2022 to 2029 CAGR: 4.3% Market Size in 2029: US $ 366.85 Bn. Segments Covered: by Drug Category • Acid Neutralizers o Antacids o H2 Antagonists o Proton Pump Inhibitors • Helicobacter Pylori Eradication • Laxatives and Anti-diarrheal • Antiemetic and Antinauseants • Anti-inflammatory Drugs • Biologics • Others by Route of Administration • Oral • Parenteral • Rectal by Disease Type •Gastroesophageal Reflux Disorder • Irritable Bowel Syndrome • Others by End-User • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies Gastrointestinal Drugs Market, by Region
• North America • Europe • Asia Pacific • Middle East & Africa • South AmericaGastrointestinal Drugs Market Key Players are:
• AbbVie Inc. • AstraZeneca • Johnson & Johnson • Abbott Laboratories • Allergan Plc • Bayer AG • Janssen Biotech Inc. • Takeda Pharmaceutical Company Limited • Eisai Co.Ltd. • Valeant Pharmaceuticals • Sanofi • Janssen Biotech • GlaxoSmithKline Plc • Boehringer Ingelheim GmbH • Novo Nordisk A/S • Teva • Zeria • Perrigo • Purdue Pharma • C.B. FleetFrequently Asked questions
1. What is the market size of the Global Gastrointestinal Drugs Market in 2021? Ans. The market size Global Gastrointestinal Drugs Market in 2021 was US$ 261.95 Billion. 2. What are the different segments of the Global Gastrointestinal Drugs Market? Ans. The Global Gastrointestinal Drugs Market is divided into Disease Type, Drug Category , Route of Administration and End-User. 3. What is the study period of this market? Ans. The Global Gastrointestinal Drugs Market will be studied from 2021 to 2029. 4. Which region is expected to hold the highest Global Gastrointestinal Drugs Market share? Ans. The Asia Pacific dominates the market share in the market. 5. What is the Forecast Period of Global Gastrointestinal Drugs Market? Ans. The Forecast Period of the market is 2022-2029 in the market.
Global Gastrointestinal Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Gastrointestinal Drugs Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Gastrointestinal Drugs Market Analysis and Forecast 6.1. Global Gastrointestinal Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Gastrointestinal Drugs Market Analysis and Forecast, by Drug Category 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Gastrointestinal Drugs Market Value Share Analysis, by Drug Category 7.4. Global Gastrointestinal Drugs Market Size (US$ Bn) Forecast, by Drug Category 7.5. Global Gastrointestinal Drugs Market Analysis, by Drug Category 7.6. Global Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Category 8. Global Gastrointestinal Drugs Market Analysis and Forecast, by Route of Administration 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration 8.4. Global Gastrointestinal Drugs Market Size (US$ Bn) Forecast, by Route of Administration 8.5. Global Gastrointestinal Drugs Market Analysis, by Route of Administration 8.6. Global Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration 9. Global Gastrointestinal Drugs Market Analysis and Forecast, by Disease Type 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Gastrointestinal Drugs Market Value Share Analysis, by Disease Type 9.4. Global Gastrointestinal Drugs Market Size (US$ Bn) Forecast, by Disease Type 9.5. Global Gastrointestinal Drugs Market Analysis, by Disease Type 9.6. Global Gastrointestinal Drugs Market Attractiveness Analysis, by Disease Type 10. Global Gastrointestinal Drugs Market Analysis and Forecast, by End-Users 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Gastrointestinal Drugs Market Value Share Analysis, by End-Users 10.4. Global Gastrointestinal Drugs Market Size (US$ Bn) Forecast, by End-Users 10.5. Global Gastrointestinal Drugs Market Analysis, by End-Users 10.6. Global Gastrointestinal Drugs Market Attractiveness Analysis, by End-Users 11. Global Gastrointestinal Drugs Market Analysis, by Region 11.1. Global Gastrointestinal Drugs Market Value Share Analysis, by Region 11.2. Global Gastrointestinal Drugs Market Size (US$ Bn) Forecast, by Region 11.3. Global Gastrointestinal Drugs Market Attractiveness Analysis, by Region 12. North America Gastrointestinal Drugs Market Analysis 12.1. Key Findings 12.2. North America Gastrointestinal Drugs Market Overview 12.3. North America Gastrointestinal Drugs Market Value Share Analysis, by Drug Category 12.4. North America Gastrointestinal Drugs Market Forecast, by Drug Category 12.4.1. Acid Neutralizers 12.4.1.1. Antacids 12.4.1.2. H2 Antagonists 12.4.1.3. Proton Pump Inhibitors 12.4.2. Helicobacter Pylori Eradication 12.4.3. Laxatives and Anti-diarrheal 12.4.4. Antiemetic and Antinauseants 12.4.5. Anti-inflammatory Drugs 12.4.6. Biologics 12.4.7. Others 12.5. North America Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration 12.6. North America Gastrointestinal Drugs Market Forecast, by Route of Administration 12.6.1. Oral 12.6.2. Parenteral 12.6.3. Rectal 12.7. North America Gastrointestinal Drugs Market Value Share Analysis, by Disease Type 12.8. North America Gastrointestinal Drugs Market Forecast, by Disease Type 12.8.1. Gastroesophageal Reflux Disorder 12.8.2. Irritable Bowel Syndrome 12.8.3. Others 12.9. North America Gastrointestinal Drugs Market Value Share Analysis, by End-Users 12.10. North America Gastrointestinal Drugs Market Forecast, by End-Users 12.10.1. Hospital Pharmacies 12.10.2. Retail Pharmacies 12.10.3. Online Pharmacies 12.11. North America Gastrointestinal Drugs Market Value Share Analysis, by Country 12.12. North America Gastrointestinal Drugs Market Forecast, by Country 12.12.1. U.S. 12.12.2. Canada 12.13. North America Gastrointestinal Drugs Market Analysis, by Country 12.14. U.S. Gastrointestinal Drugs Market Forecast, by Drug Category 12.14.1. Acid Neutralizers 12.14.1.1. Antacids 12.14.1.2. H2 Antagonists 12.14.1.3. Proton Pump Inhibitors 12.14.2. Helicobacter Pylori Eradication 12.14.3. Laxatives and Anti-diarrheal 12.14.4. Antiemetic and Antinauseants 12.14.5. Anti-inflammatory Drugs 12.14.6. Biologics 12.14.7. Others 12.15. U.S. Gastrointestinal Drugs Market Forecast, by Route of Administration 12.15.1. Oral 12.15.2. Parenteral 12.15.3. Rectal 12.16. U.S. Gastrointestinal Drugs Market Forecast, by Disease Type 12.16.1. Gastroesophageal Reflux Disorder 12.16.2. Irritable Bowel Syndrome 12.16.3. Others 12.17. U.S. Gastrointestinal Drugs Market Forecast, by End-Users 12.17.1. Hospital Pharmacies 12.17.2. Retail Pharmacies 12.17.3. Online Pharmacies 12.18. Canada Gastrointestinal Drugs Market Forecast, by Drug Category 12.18.1. Acid Neutralizers 12.18.1.1. Antacids 12.18.1.2. H2 Antagonists 12.18.1.3. Proton Pump Inhibitors 12.18.2. Helicobacter Pylori Eradication 12.18.3. Laxatives and Anti-diarrheal 12.18.4. Antiemetic and Antinauseants 12.18.5. Anti-inflammatory Drugs 12.18.6. Biologics 12.18.7. Others 12.19. Canada Gastrointestinal Drugs Market Forecast, by Route of Administration 12.19.1. Oral 12.19.2. Parenteral 12.19.3. Rectal 12.20. Canada Gastrointestinal Drugs Market Forecast, by Disease Type 12.20.1. Gastroesophageal Reflux Disorder 12.20.2. Irritable Bowel Syndrome 12.20.3. Others 12.21. Canada Gastrointestinal Drugs Market Forecast, by End-Users 12.21.1. Hospital Pharmacies 12.21.2. Retail Pharmacies 12.21.3. Online Pharmacies 12.22. North America Gastrointestinal Drugs Market Attractiveness Analysis 12.22.1. By Drug Category 12.22.2. By Route of Administration 12.22.3. By Disease Type 12.22.4. By End-Users 12.23. PEST Analysis 12.24. Key Trends 12.25. Key Developments 13. Europe Gastrointestinal Drugs Market Analysis 13.1. Key Findings 13.2. Europe Gastrointestinal Drugs Market Overview 13.3. Europe Gastrointestinal Drugs Market Value Share Analysis, by Drug Category 13.4. Europe Gastrointestinal Drugs Market Forecast, by Drug Category 13.4.1. Acid Neutralizers 13.4.1.1. Antacids 13.4.1.2. H2 Antagonists 13.4.1.3. Proton Pump Inhibitors 13.4.2. Helicobacter Pylori Eradication 13.4.3. Laxatives and Anti-diarrheal 13.4.4. Antiemetic and Antinauseants 13.4.5. Anti-inflammatory Drugs 13.4.6. Biologics 13.4.7. Others 13.5. Europe Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration 13.6. Europe Gastrointestinal Drugs Market Forecast, by Route of Administration 13.6.1. Oral 13.6.2. Parenteral 13.6.3. Rectal 13.7. Europe Gastrointestinal Drugs Market Value Share Analysis, by Disease Type 13.8. Europe Gastrointestinal Drugs Market Forecast, by Disease Type 13.8.1. Gastroesophageal Reflux Disorder 13.8.2. Irritable Bowel Syndrome 13.8.3. Others 13.9. Europe Gastrointestinal Drugs Market Value Share Analysis, by End-Users 13.10. Europe Gastrointestinal Drugs Market Forecast, by End-Users 13.10.1. Hospital Pharmacies 13.10.2. Retail Pharmacies 13.10.3. Online Pharmacies 13.11. Europe Gastrointestinal Drugs Market Value Share Analysis, by Country 13.12. Europe Gastrointestinal Drugs Market Forecast, by Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Rest of Europe 13.13. Europe Gastrointestinal Drugs Market Analysis, by Country 13.14. Germany Gastrointestinal Drugs Market Forecast, by Drug Category 13.14.1. Acid Neutralizers 13.14.1.1. Antacids 13.14.1.2. H2 Antagonists 13.14.1.3. Proton Pump Inhibitors 13.14.2. Helicobacter Pylori Eradication 13.14.3. Laxatives and Anti-diarrheal 13.14.4. Antiemetic and Antinauseants 13.14.5. Anti-inflammatory Drugs 13.14.6. Biologics 13.14.7. Others 13.15. Germany Gastrointestinal Drugs Market Forecast, by Route of Administration 13.15.1. Oral 13.15.2. Parenteral 13.15.3. Rectal 13.16. Germany Gastrointestinal Drugs Market Forecast, by Disease Type 13.16.1. Gastroesophageal Reflux Disorder 13.16.2. Irritable Bowel Syndrome 13.16.3. Others 13.17. Germany Gastrointestinal Drugs Market Forecast, by End-Users 13.17.1. Hospital Pharmacies 13.17.2. Retail Pharmacies 13.17.3. Online Pharmacies 13.18. U.K. Gastrointestinal Drugs Market Forecast, by Drug Category 13.18.1. Acid Neutralizers 13.18.1.1. Antacids 13.18.1.2. H2 Antagonists 13.18.1.3. Proton Pump Inhibitors 13.18.2. Helicobacter Pylori Eradication 13.18.3. Laxatives and Anti-diarrheal 13.18.4. Antiemetic and Antinauseants 13.18.5. Anti-inflammatory Drugs 13.18.6. Biologics 13.18.7. Others 13.19. U.K. Gastrointestinal Drugs Market Forecast, by Route of Administration 13.19.1. Oral 13.19.2. Parenteral 13.19.3. Rectal 13.20. U.K. Gastrointestinal Drugs Market Forecast, by Disease Type 13.20.1. Gastroesophageal Reflux Disorder 13.20.2. Irritable Bowel Syndrome 13.20.3. Others 13.21. U.K. Gastrointestinal Drugs Market Forecast, by End-Users 13.21.1. Hospital Pharmacies 13.21.2. Retail Pharmacies 13.21.3. Online Pharmacies 13.22. France Gastrointestinal Drugs Market Forecast, by Drug Category 13.22.1. Acid Neutralizers 13.22.1.1. Antacids 13.22.1.2. H2 Antagonists 13.22.1.3. Proton Pump Inhibitors 13.22.2. Helicobacter Pylori Eradication 13.22.3. Laxatives and Anti-diarrheal 13.22.4. Antiemetic and Antinauseants 13.22.5. Anti-inflammatory Drugs 13.22.6. Biologics 13.22.7. Others 13.23. France Gastrointestinal Drugs Market Forecast, by Route of Administration 13.23.1. Oral 13.23.2. Parenteral 13.23.3. Rectal 13.24. France Gastrointestinal Drugs Market Forecast, by Disease Type 13.24.1. Gastroesophageal Reflux Disorder 13.24.2. Irritable Bowel Syndrome 13.24.3. Others 13.25. France Gastrointestinal Drugs Market Forecast, by End-Users 13.25.1. Hospital Pharmacies 13.25.2. Retail Pharmacies 13.25.3. Online Pharmacies 13.26. Italy Gastrointestinal Drugs Market Forecast, by Drug Category 13.26.1. Acid Neutralizers 13.26.1.1. Antacids 13.26.1.2. H2 Antagonists 13.26.1.3. Proton Pump Inhibitors 13.26.2. Helicobacter Pylori Eradication 13.26.3. Laxatives and Anti-diarrheal 13.26.4. Antiemetic and Antinauseants 13.26.5. Anti-inflammatory Drugs 13.26.6. Biologics 13.26.7. Others 13.27. Italy Gastrointestinal Drugs Market Forecast, by Route of Administration 13.27.1. Oral 13.27.2. Parenteral 13.27.3. Rectal 13.28. Italy Gastrointestinal Drugs Market Forecast, by Disease Type 13.28.1. Gastroesophageal Reflux Disorder 13.28.2. Irritable Bowel Syndrome 13.28.3. Others 13.29. Italy Gastrointestinal Drugs Market Forecast, by End-Users 13.29.1. Hospital Pharmacies 13.29.2. Retail Pharmacies 13.29.3. Online Pharmacies 13.30. Spain Gastrointestinal Drugs Market Forecast, by Drug Category 13.30.1. Acid Neutralizers 13.30.1.1. Antacids 13.30.1.2. H2 Antagonists 13.30.1.3. Proton Pump Inhibitors 13.30.2. Helicobacter Pylori Eradication 13.30.3. Laxatives and Anti-diarrheal 13.30.4. Antiemetic and Antinauseants 13.30.5. Anti-inflammatory Drugs 13.30.6. Biologics 13.30.7. Others 13.31. Spain Gastrointestinal Drugs Market Forecast, by Route of Administration 13.31.1. Oral 13.31.2. Parenteral 13.31.3. Rectal 13.32. Spain Gastrointestinal Drugs Market Forecast, by Disease Type 13.32.1. Gastroesophageal Reflux Disorder 13.32.2. Irritable Bowel Syndrome 13.32.3. Others 13.33. Spain Gastrointestinal Drugs Market Forecast, by End-Users 13.33.1. Hospital Pharmacies 13.33.2. Retail Pharmacies 13.33.3. Online Pharmacies 13.34. Rest of Europe Gastrointestinal Drugs Market Forecast, by Drug Category 13.34.1. Acid Neutralizers 13.34.1.1. Antacids 13.34.1.2. H2 Antagonists 13.34.1.3. Proton Pump Inhibitors 13.34.2. Helicobacter Pylori Eradication 13.34.3. Laxatives and Anti-diarrheal 13.34.4. Antiemetic and Antinauseants 13.34.5. Anti-inflammatory Drugs 13.34.6. Biologics 13.34.7. Others 13.35. Rest of Europe Gastrointestinal Drugs Market Forecast, by Route of Administration 13.35.1. Oral 13.35.2. Parenteral 13.35.3. Rectal 13.36. Rest of Europe Gastrointestinal Drugs Market Forecast, by Disease Type 13.36.1. Gastroesophageal Reflux Disorder 13.36.2. Irritable Bowel Syndrome 13.36.3. Others 13.37. Rest Of Europe Gastrointestinal Drugs Market Forecast, by End-Users 13.37.1. Hospital Pharmacies 13.37.2. Retail Pharmacies 13.37.3. Online Pharmacies 13.38. Europe Gastrointestinal Drugs Market Attractiveness Analysis 13.38.1. By Drug Category 13.38.2. By Route of Administration 13.38.3. By Disease Type 13.38.4. By End-Users 13.39. PEST Analysis 13.40. Key Trends 13.41. Key Developments 14. Asia Pacific Gastrointestinal Drugs Market Analysis 14.1. Key Findings 14.2. Asia Pacific Gastrointestinal Drugs Market Overview 14.3. Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Drug Category 14.4. Asia Pacific Gastrointestinal Drugs Market Forecast, by Drug Category 14.4.1. Acid Neutralizers 14.4.1.1. Antacids 14.4.1.2. H2 Antagonists 14.4.1.3. Proton Pump Inhibitors 14.4.2. Helicobacter Pylori Eradication 14.4.3. Laxatives and Anti-diarrheal 14.4.4. Antiemetic and Antinauseants 14.4.5. Anti-inflammatory Drugs 14.4.6. Biologics 14.4.7. Others 14.5. Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration 14.6. Asia Pacific Gastrointestinal Drugs Market Forecast, by Route of Administration 14.6.1. Oral 14.6.2. Parenteral 14.6.3. Rectal 14.7. Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Disease Type 14.8. Asia Pacific Gastrointestinal Drugs Market Forecast, by Disease Type 14.8.1. Gastroesophageal Reflux Disorder 14.8.2. Irritable Bowel Syndrome 14.8.3. Others 14.9. Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by End-Users 14.10. Asia Pacific Gastrointestinal Drugs Market Forecast, by End-Users 14.10.1. Hospital Pharmacies 14.10.2. Retail Pharmacies 14.10.3. Online Pharmacies 14.11. Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Country 14.12. Asia Pacific Gastrointestinal Drugs Market Forecast, by Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. ASEAN 14.12.5. Rest of Asia Pacific 14.13. Asia Pacific Gastrointestinal Drugs Market Analysis, by Country 14.14. China Gastrointestinal Drugs Market Forecast, by Drug Category 14.14.1. Acid Neutralizers 14.14.1.1. Antacids 14.14.1.2. H2 Antagonists 14.14.1.3. Proton Pump Inhibitors 14.14.2. Helicobacter Pylori Eradication 14.14.3. Laxatives and Anti-diarrheal 14.14.4. Antiemetic and Antinauseants 14.14.5. Anti-inflammatory Drugs 14.14.6. Biologics 14.14.7. Others 14.15. China Gastrointestinal Drugs Market Forecast, by Route of Administration 14.15.1. Oral 14.15.2. Parenteral 14.15.3. Rectal 14.16. China Gastrointestinal Drugs Market Forecast, by Disease Type 14.16.1. Gastroesophageal Reflux Disorder 14.16.2. Irritable Bowel Syndrome 14.16.3. Others 14.17. China Gastrointestinal Drugs Market Forecast, by End-Users 14.17.1. Hospital Pharmacies 14.17.2. Retail Pharmacies 14.17.3. Online Pharmacies 14.18. India Gastrointestinal Drugs Market Forecast, by Drug Category 14.18.1. Acid Neutralizers 14.18.1.1. Antacids 14.18.1.2. H2 Antagonists 14.18.1.3. Proton Pump Inhibitors 14.18.2. Helicobacter Pylori Eradication 14.18.3. Laxatives and Anti-diarrheal 14.18.4. Antiemetic and Antinauseants 14.18.5. Anti-inflammatory Drugs 14.18.6. Biologics 14.18.7. Others 14.19. India Gastrointestinal Drugs Market Forecast, by Route of Administration 14.19.1. Oral 14.19.2. Parenteral 14.19.3. Rectal 14.20. India Gastrointestinal Drugs Market Forecast, by Disease Type 14.20.1. Gastroesophageal Reflux Disorder 14.20.2. Irritable Bowel Syndrome 14.20.3. Others 14.21. India Gastrointestinal Drugs Market Forecast, by End-Users 14.21.1. Hospital Pharmacies 14.21.2. Retail Pharmacies 14.21.3. Online Pharmacies 14.22. Japan Gastrointestinal Drugs Market Forecast, by Drug Category 14.22.1. Acid Neutralizers 14.22.1.1. Antacids 14.22.1.2. H2 Antagonists 14.22.1.3. Proton Pump Inhibitors 14.22.2. Helicobacter Pylori Eradication 14.22.3. Laxatives and Anti-diarrheal 14.22.4. Antiemetic and Antinauseants 14.22.5. Anti-inflammatory Drugs 14.22.6. Biologics 14.22.7. Others 14.23. Japan Gastrointestinal Drugs Market Forecast, by Route of Administration 14.23.1. Oral 14.23.2. Parenteral 14.23.3. Rectal 14.24. Japan Gastrointestinal Drugs Market Forecast, by Disease Type 14.24.1. Gastroesophageal Reflux Disorder 14.24.2. Irritable Bowel Syndrome 14.24.3. Others 14.25. Japan Gastrointestinal Drugs Market Forecast, by End-Users 14.25.1. Hospital Pharmacies 14.25.2. Retail Pharmacies 14.25.3. Online Pharmacies 14.26. ASEAN Gastrointestinal Drugs Market Forecast, by Drug Category 14.26.1. Acid Neutralizers 14.26.1.1. Antacids 14.26.1.2. H2 Antagonists 14.26.1.3. Proton Pump Inhibitors 14.26.2. Helicobacter Pylori Eradication 14.26.3. Laxatives and Anti-diarrheal 14.26.4. Antiemetic and Antinauseants 14.26.5. Anti-inflammatory Drugs 14.26.6. Biologics 14.26.7. Others 14.27. ASEAN Gastrointestinal Drugs Market Forecast, by Route of Administration 14.27.1. Oral 14.27.2. Parenteral 14.27.3. Rectal 14.28. ASEAN Gastrointestinal Drugs Market Forecast, by Disease Type 14.28.1. Gastroesophageal Reflux Disorder 14.28.2. Irritable Bowel Syndrome 14.28.3. Others 14.29. ASEAN Gastrointestinal Drugs Market Forecast, by End-Users 14.29.1. Hospital Pharmacies 14.29.2. Retail Pharmacies 14.29.3. Online Pharmacies 14.30. Rest of Asia Pacific Gastrointestinal Drugs Market Forecast, by Drug Category 14.30.1. Acid Neutralizers 14.30.1.1. Antacids 14.30.1.2. H2 Antagonists 14.30.1.3. Proton Pump Inhibitors 14.30.2. Helicobacter Pylori Eradication 14.30.3. Laxatives and Anti-diarrheal 14.30.4. Antiemetic and Antinauseants 14.30.5. Anti-inflammatory Drugs 14.30.6. Biologics 14.30.7. Others 14.31. Rest of Asia Pacific Gastrointestinal Drugs Market Forecast, by Route of Administration 14.31.1. Oral 14.31.2. Parenteral 14.31.3. Rectal 14.32. Rest of Asia Pacific Gastrointestinal Drugs Market Forecast, by Disease Type 14.32.1. Gastroesophageal Reflux Disorder 14.32.2. Irritable Bowel Syndrome 14.32.3. Others 14.33. Rest of Asia Pacific Gastrointestinal Drugs Market Forecast, by End-Users 14.33.1. Hospital Pharmacies 14.33.2. Retail Pharmacies 14.33.3. Online Pharmacies 14.34. Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis 14.34.1. By Drug Category 14.34.2. By Route of Administration 14.34.3. By Disease Type 14.34.4. By End-Users 14.35. PEST Analysis 14.36. Key Trends 14.37. Key Developments 15. Middle East & Africa Gastrointestinal Drugs Market Analysis 15.1. Key Findings 15.2. Middle East & Africa Gastrointestinal Drugs Market Overview 15.3. Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Drug Category 15.4. Middle East & Africa Gastrointestinal Drugs Market Forecast, by Drug Category 15.4.1. Acid Neutralizers 15.4.1.1. Antacids 15.4.1.2. H2 Antagonists 15.4.1.3. Proton Pump Inhibitors 15.4.2. Helicobacter Pylori Eradication 15.4.3. Laxatives and Anti-diarrheal 15.4.4. Antiemetic and Antinauseants 15.4.5. Anti-inflammatory Drugs 15.4.6. Biologics 15.4.7. Others 15.5. Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration 15.6. Middle East & Africa Gastrointestinal Drugs Market Forecast, by Route of Administration 15.6.1. Oral 15.6.2. Parenteral 15.6.3. Rectal 15.7. Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Disease Type 15.8. Middle East & Africa Gastrointestinal Drugs Market Forecast, by Disease Type 15.8.1. Gastroesophageal Reflux Disorder 15.8.2. Irritable Bowel Syndrome 15.8.3. Others 15.9. Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by End-Users 15.10. Middle East & Africa Gastrointestinal Drugs Market Forecast, by End-Users 15.10.1. Hospital Pharmacies 15.10.2. Retail Pharmacies 15.10.3. Online Pharmacies 15.11. Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Country 15.12. Middle East & Africa Gastrointestinal Drugs Market Forecast, by Country 15.12.1. GCC 15.12.2. South Africa 15.12.3. Rest of Middle East & Africa 15.13. Middle East & Africa Gastrointestinal Drugs Market Analysis, by Country 15.14. GCC Gastrointestinal Drugs Market Forecast, by Drug Category 15.14.1. Acid Neutralizers 15.14.1.1. Antacids 15.14.1.2. H2 Antagonists 15.14.1.3. Proton Pump Inhibitors 15.14.2. Helicobacter Pylori Eradication 15.14.3. Laxatives and Anti-diarrheal 15.14.4. Antiemetic and Antinauseants 15.14.5. Anti-inflammatory Drugs 15.14.6. Biologics 15.14.7. Others 15.15. GCC Gastrointestinal Drugs Market Forecast, by Route of Administration 15.15.1. Oral 15.15.2. Parenteral 15.15.3. Rectal 15.16. GCC Gastrointestinal Drugs Market Forecast, by Disease Type 15.16.1. Gastroesophageal Reflux Disorder 15.16.2. Irritable Bowel Syndrome 15.16.3. Others 15.17. GCC Gastrointestinal Drugs Market Forecast, by End-Users 15.17.1. Hospital Pharmacies 15.17.2. Retail Pharmacies 15.17.3. Online Pharmacies 15.18. South Africa Gastrointestinal Drugs Market Forecast, by Drug Category 15.18.1. Acid Neutralizers 15.18.1.1. Antacids 15.18.1.2. H2 Antagonists 15.18.1.3. Proton Pump Inhibitors 15.18.2. Helicobacter Pylori Eradication 15.18.3. Laxatives and Anti-diarrheal 15.18.4. Antiemetic and Antinauseants 15.18.5. Anti-inflammatory Drugs 15.18.6. Biologics 15.18.7. Others 15.19. South Africa Gastrointestinal Drugs Market Forecast, by Route of Administration 15.19.1. Oral 15.19.2. Parenteral 15.19.3. Rectal 15.20. South Africa Gastrointestinal Drugs Market Forecast, by Disease Type 15.20.1. Gastroesophageal Reflux Disorder 15.20.2. Irritable Bowel Syndrome 15.20.3. Others 15.21. South Africa Gastrointestinal Drugs Market Forecast, by End-Users 15.21.1. Hospital Pharmacies 15.21.2. Retail Pharmacies 15.21.3. Online Pharmacies 15.22. Rest of Middle East & Africa Gastrointestinal Drugs Market Forecast, by Drug Category 15.22.1. Acid Neutralizers 15.22.1.1. Antacids 15.22.1.2. H2 Antagonists 15.22.1.3. Proton Pump Inhibitors 15.22.2. Helicobacter Pylori Eradication 15.22.3. Laxatives and Anti-diarrheal 15.22.4. Antiemetic and Antinauseants 15.22.5. Anti-inflammatory Drugs 15.22.6. Biologics 15.22.7. Others 15.23. Rest of Middle East & Africa Gastrointestinal Drugs Market Forecast, by Route of Administration 15.23.1. Oral 15.23.2. Parenteral 15.23.3. Rectal 15.24. Rest of Middle East & Africa Gastrointestinal Drugs Market Forecast, by Disease Type 15.24.1. Gastroesophageal Reflux Disorder 15.24.2. Irritable Bowel Syndrome 15.24.3. Others 15.25. Rest of Middle East & Africa Gastrointestinal Drugs Market Forecast, by End-Users 15.25.1. Hospital Pharmacies 15.25.2. Retail Pharmacies 15.25.3. Online Pharmacies 15.26. Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis 15.26.1. By Drug Category 15.26.2. By Route of Administration 15.26.3. By Disease Type 15.26.4. By End-Users 15.27. PEST Analysis 15.28. Key Trends 15.29. Key Developments 16. South America Gastrointestinal Drugs Market Analysis 16.1. Key Findings 16.2. South America Gastrointestinal Drugs Market Overview 16.3. South America Gastrointestinal Drugs Market Value Share Analysis, by Drug Category 16.4. South America Gastrointestinal Drugs Market Forecast, by Drug Category 16.4.1. Acid Neutralizers 16.4.1.1. Antacids 16.4.1.2. H2 Antagonists 16.4.1.3. Proton Pump Inhibitors 16.4.2. Helicobacter Pylori Eradication 16.4.3. Laxatives and Anti-diarrheal 16.4.4. Antiemetic and Antinauseants 16.4.5. Anti-inflammatory Drugs 16.4.6. Biologics 16.4.7. Others 16.5. South America Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration 16.6. South America Gastrointestinal Drugs Market Forecast, by Route of Administration 16.6.1. Oral 16.6.2. Parenteral 16.6.3. Rectal 16.7. South America Gastrointestinal Drugs Market Value Share Analysis, by Disease Type 16.8. South America Gastrointestinal Drugs Market Forecast, by Disease Type 16.8.1. Gastroesophageal Reflux Disorder 16.8.2. Irritable Bowel Syndrome 16.8.3. Others 16.9. South America Gastrointestinal Drugs Market Value Share Analysis, by End-Users 16.10. South America Gastrointestinal Drugs Market Forecast, by End-Users 16.10.1. Hospital Pharmacies 16.10.2. Retail Pharmacies 16.10.3. Online Pharmacies 16.11. South America Gastrointestinal Drugs Market Value Share Analysis, by Country 16.12. South America Gastrointestinal Drugs Market Forecast, by Country 16.12.1. Brazil 16.12.2. Mexico 16.12.3. Rest of South America 16.13. South America Gastrointestinal Drugs Market Analysis, by Country 16.14. Brazil Gastrointestinal Drugs Market Forecast, by Drug Category 16.14.1. Acid Neutralizers 16.14.1.1. Antacids 16.14.1.2. H2 Antagonists 16.14.1.3. Proton Pump Inhibitors 16.14.2. Helicobacter Pylori Eradication 16.14.3. Laxatives and Anti-diarrheal 16.14.4. Antiemetic and Antinauseants 16.14.5. Anti-inflammatory Drugs 16.14.6. Biologics 16.14.7. Others 16.15. Brazil Gastrointestinal Drugs Market Forecast, by Route of Administration 16.15.1. Oral 16.15.2. Parenteral 16.15.3. Rectal 16.16. Brazil Gastrointestinal Drugs Market Forecast, by Disease Type 16.16.1. Gastroesophageal Reflux Disorder 16.16.2. Irritable Bowel Syndrome 16.16.3. Others 16.17. Brazil Gastrointestinal Drugs Market Forecast, by End-Users 16.17.1. Hospital Pharmacies 16.17.2. Retail Pharmacies 16.17.3. Online Pharmacies 16.18. Mexico Gastrointestinal Drugs Market Forecast, by Drug Category 16.18.1. Acid Neutralizers 16.18.1.1. Antacids 16.18.1.2. H2 Antagonists 16.18.1.3. Proton Pump Inhibitors 16.18.2. Helicobacter Pylori Eradication 16.18.3. Laxatives and Anti-diarrheal 16.18.4. Antiemetic and Antinauseants 16.18.5. Anti-inflammatory Drugs 16.18.6. Biologics 16.18.7. Others 16.19. Mexico Gastrointestinal Drugs Market Forecast, by Route of Administration 16.19.1. Oral 16.19.2. Parenteral 16.19.3. Rectal 16.20. Mexico Gastrointestinal Drugs Market Forecast, by Disease Type 16.20.1. Gastroesophageal Reflux Disorder 16.20.2. Irritable Bowel Syndrome 16.20.3. Others 16.21. Mexico Gastrointestinal Drugs Market Forecast, by End-Users 16.21.1. Hospital Pharmacies 16.21.2. Retail Pharmacies 16.21.3. Online Pharmacies 16.22. Rest of South America Gastrointestinal Drugs Market Forecast, by Drug Category 16.22.1. Acid Neutralizers 16.22.1.1. Antacids 16.22.1.2. H2 Antagonists 16.22.1.3. Proton Pump Inhibitors 16.22.2. Helicobacter Pylori Eradication 16.22.3. Laxatives and Anti-diarrheal 16.22.4. Antiemetic and Antinauseants 16.22.5. Anti-inflammatory Drugs 16.22.6. Biologics 16.22.7. Others 16.23. Rest of South America Gastrointestinal Drugs Market Forecast, by Route of Administration 16.23.1. Oral 16.23.2. Parenteral 16.23.3. Rectal 16.24. Rest of South America Gastrointestinal Drugs Market Forecast, by Disease Type 16.24.1. Gastroesophageal Reflux Disorder 16.24.2. Irritable Bowel Syndrome 16.24.3. Others 16.25. Rest of South America Gastrointestinal Drugs Market Forecast, by End-Users 16.25.1. Hospital Pharmacies 16.25.2. Retail Pharmacies 16.25.3. Online Pharmacies 16.26. South America Gastrointestinal Drugs Market Attractiveness Analysis 16.26.1. By Drug Category 16.26.2. By Route of Administration 16.26.3. By Disease Type 16.26.4. By End-Users 16.27. PEST Analysis 16.28. Key Trends 16.29. Key Developments 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A by Regions, Investment and Applications 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.3. Company Profiles: Key Players 17.3.1. AbbVie Inc. 17.3.1.1. Company Overview 17.3.1.2. Financial Overview 17.3.1.3. Product Portfolio 17.3.1.4. Business Strategy 17.3.1.5. Recent Developments 17.3.1.6. Development Footprint 17.3.2. AstraZeneca 17.3.3. Johnson & Johnson 17.3.4. Abbott Laboratories 17.3.5. Allergan Plc 17.3.6. Bayer AG 17.3.7. Janssen Biotech Inc. 17.3.8. Takeda Pharmaceutical Company Limited 17.3.9. Eisai Co.Ltd. 17.3.10. Valeant Pharmaceuticals 17.3.11. Sanofi 17.3.12. Janssen Biotech 17.3.13. GlaxoSmithKline Plc 17.3.14. Boehringer Ingelheim GmbH 17.3.15. Novo Nordisk A/S 17.3.16. Teva 17.3.17. Zeria 17.3.18. Perrigo 17.3.19. Purdue Pharma 17.3.20. C.B. Fleet 18. Primary Key Insights